{"schema_version":"secwatch.filing_event.v1","accession":"0001860742-25-000003","form_type":"8-K","ticker":"BLCO","cik":"0001860742","company_name":"Bausch & Lomb Corp","filed_at":"2025-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.357429+00:00","generated_at":"2026-05-26T12:30:07.476362+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bausch + Lomb Q4 revenue up 11% CC; FY GAAP loss widens; guides 2025 revenue ~$5B","bullets":["Q4 revenue $1.28B, up 9% reported and 11% constant currency, with growth across all segments.","FY GAAP net loss attributable $317M vs $260M loss in 2023; adjusted net income $204M vs $258M.","Adjusted EBITDA ex Acquired IPR&D FY $878M (+$140M); Q4 $259M (+$28M).","2025 guidance: revenue $4.95B-$5.05B (~5.5%-7.5% CC growth); Adj. EBITDA $900M-$950M; FX headwinds ~$100M revenue.","Dry eye portfolio approaching $1B annual revenue; contact lens double-digit Q4 growth; XIIDRA/MIEBO driving pharma."],"urls":{"canonical":"https://secwatch.observer/filing/0001860742-25-000003","json":"https://secwatch.observer/filing/0001860742-25-000003.json","markdown":"https://secwatch.observer/filing/0001860742-25-000003.md","text":"https://secwatch.observer/filing/0001860742-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860742/000186074225000003/0001860742-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860742/000186074225000003/blco-20250219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T12:30:07.476362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}